Harrill AH, Desmet KD, Wolf KK, Bridges AS, Eaddy JS, Kurtz CL, Hall JE, Paine MF, Tidwell RR, Watkins PB. A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models.
Toxicol Sci. 2012 Dec;130(2):416-26. doi: 10.1093/toxsci/kfs238. Epub 2012 Aug 31.
MPD curation note: DB289 was previously tested in clinical trials to treat African trypanosomiasis. However, the trial was terminated when subjects developed severe kidney injury, an effect not predicted from preclinical testing. This project (Harrill2) highlights the utility of inbred strains to predict clinically relevant toxicities to drugs prior to clinical trials.
Alison Harrill University of Arkansas for Medical Sciences Little Rock, AR|
|Contact||Alison Harrill AHHarrill@uams.edu
|Acknowledgements||Funding provided by the Bill and Melinda Gates Foundation.|
|Phenotype strain survey data set|
|MPD identifiers||Harrill2 MPD:441|
|No updates/corrections. Initial release date: 12/2012.|
Click above to copy-paste the entire citation for this MPD web page.
|Summary of procedures that were conducted|
|• body weight||DB289-treated vs. control.|
|• metabolic panel||Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control.|
|• urinalysis||Urine volume, creatinine. DB289-treated vs. control.|
|• biomarker quantification||Kidney injury molecule 1 (KIM-1). DB289-treated vs. control.|
|• organ weights||Kidney and liver weights. DB289-treated vs. control.|
|• drug and metabolite quantification||Kidney metabolite (DB75) concentration. DB289-treated vs. control.|